文献速递临床免疫质量管理与危急值

尿液合成大麻素免疫筛查的诊断效能评估

Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency.
PubMed 文献 · Clin Chem Lab Med · 2017-01-01

两项回顾性研究评估两种均相酶免疫分析法在真实尿液样本中检测当前流行合成大麻素的能力,以LC-ESI-MS/MS确认。第一项研究(n=549)中免疫法全部阴性而LC-MS/MS显示8%阳性;第二项研究(n=200)联合两种试剂盒的灵敏度仅2%、诊断准确率51%。结论强烈建议临床或法医场景不应依赖所评估的免疫法。

要点

  • 所评估的两种合成大麻素尿液免疫法灵敏度极低,联合应用仅2%。
  • 免疫法阴性不能排除合成大麻素使用,需以LC-MS/MS确认。
  • 抗体对当前流行合成大麻素交叉反应不足且检测限较高。

核心结论

  • 强烈建议临床或法医场景不应依赖所评估的合成大麻素尿液免疫法。
  • 其他供应商的免疫试剂盒预期会有类似结果。

研究设计与样本

  • 两项回顾性研究,使用真实尿液样本评估两种均相酶免疫分析法(JWH-018试剂盒和UR-144试剂盒)。
  • 免疫法结果由覆盖45种合成大麻素代谢物的LC-ESI-MS/MS筛查方法确认。
  • 第一项研究样本量n=549,第二项研究样本量n=200。

主要发现

  • 第一项研究(n=549)中LC-MS/MS显示8%的合成大麻素使用流行率,而所有样本免疫法均为阴性。
  • 第二项研究(n=200)中联合应用两种免疫法在推荐cut-off下灵敏度为2%、诊断准确率为51%。
  • 该人群中检出10种不同的当前流行合成大麻素。
  • 结果可归因于抗体对当前合成大麻素交叉反应不足及免疫法检测限相对较高。

临床怎么用

  • 临床或法医场景不应依赖所评估的合成大麻素尿液免疫法进行筛查。
  • 免疫法阴性结果不能排除合成大麻素使用,需用LC-MS/MS确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The abuse of synthetic cannabinoids (SCs) as presumed legal alternative to cannabis poses a great risk to public health. For economic reasons many laboratories use immunoassays (IAs) to screen for these substances in urine. However, the structural diversity and high potency of these designer drugs places high demands on IAs regarding cross-reactivity of the antibodies used and detection limits. METHODS: Two retrospective studies were carried out in order to evaluate the capability of two homogenous enzyme IAs for the detection of currently prevalent SCs in authentic urine samples. Urine samples were analyzed utilizing a 'JWH-018' kit and a 'UR-144' kit. The IA results were confirmed by an up-to-date liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) screening method covering metabolites of 45 SCs. RESULTS: The first study (n=549) showed an 8% prevalence of SCs use (LC-MS/MS analysis) among inpatients of forensic-psychiatric clinics, whereas all samples were tested negative by the IAs. In a second study (n=200) the combined application of both IAs led to a sensitivity of 2% and a diagnostic accuracy of 51% when applying the recommended IA cut-offs. Overall, 10 different currently prevalent SCs were detected in this population. The results can be explained by an insufficient cross-reactivity of the antibodies towards current SCs in combination with relatively high detection limits of the IAs. CONCLUSIONS: In light of the presented study data it is strongly recommended not to rely on the evaluated IA tests for SCs in clinical or forensic settings. For IA kits of other providers similar results can be expected.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Franz F, Angerer V, Jechle H, et al. Immunoassay screening in urine for synthetic cannabinoids - an evaluation of the diagnostic efficiency. Clin Chem Lab Med. 2017. PMID: 28130957. doi:10.1515/cclm-2016-0831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。